Mutational processes shape the landscape of TP53 mutations in human cancer

Nature Genetics

Volumn 50, Issue 10, 2018, Pages 1381-1387

  Giacomelli, Andrew O ^a,b   Yang, Xiaoping ^b   Lintner, Robert E ^b   McFarland, James M ^b   Duby, Marc ^b   Kim, Jaegil ^b   Howard, Thomas P ^a,b,c   Takeda, David Y ^a,b,c   Ly, Seav Huong ^a,b   Kim, Eejung ^b   Gannon, Hugh S ^a,b   Hurhula, Brian ^b   Sharpe, Ted ^b   Goodale, Amy ^b   Fritchman, Briana ^b   Steelman, Scott ^b   Vazquez, Francisca ^a,b   Tsherniak, Aviad ^b   Aguirre, Andrew J ^a,b   Doench, John G ^b   Piccioni, Federica ^b   Roberts, Charles W M ^a,c,d   Meyerson, Matthew ^a,b,c   Getz, Gad ^b,c,e   Johannessen, Cory M ^b   Root, David E ^b   Hahn, William C ^a,b,c,f   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLCYTOSINE; AFLATOXIN; APOLIPOPROTEIN B; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE; DOXORUBICIN; ETOPOSIDE; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; PUROMYCIN; THYMINE; TOBACCO SMOKE; TP53 PROTEIN, HUMAN;

AGING; AMINO ACID SEQUENCE; ATTENUATION; BLADDER CANCER; CELL CYCLE ARREST; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; CRISPR-CAS9 SYSTEM; DNA BINDING; DNA SEQUENCE; DOUBLE STRANDED DNA BREAK; GENE EDITING; GENETIC CONSERVATION; HUMAN; HUMAN CELL; LETTER; LIVER CANCER; LOSS OF FUNCTION MUTATION; LUNG ADENOCARCINOMA CELL LINE; LUNG CANCER; MALIGNANT NEOPLASM; MISMATCH REPAIR; MISSENSE MUTATION; MUTAGENESIS; NONHUMAN; NONSENSE MUTATION; NULL ALLELE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION EXPOSURE; SILENT MUTATION; SKIN CANCER; STABLE EXPRESSION; STOP CODON; THYMOCYTE; TRANSACTIVATION; ULTRAVIOLET RADIATION; WHOLE EXOME SEQUENCING; WILD TYPE; CANCER CELL LINE; GENE MUTATION; SOMATIC MUTATION; A-549 CELL LINE; ALLELE; CELL CULTURE; CRISPR CAS SYSTEM; DNA MUTATIONAL ANALYSIS; GENETIC DATABASE; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

A549 CELLS; ALLELES; CELLS, CULTURED; CRISPR-CAS SYSTEMS; DATABASES, GENETIC; DNA MUTATIONAL ANALYSIS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTAGENESIS; MUTATION; NEOPLASMS; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85053677289     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/s41588-018-0204-y     Document Type: Letter

References (52)

1. Hainaut, P. & Pfeifer, G. P. Somatic TP53 mutations in the era of genome sequencing. Cold Spring Harb. Perspect. Med. 6, a026179 (2016)
2. Petitjean, A. et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 28, 622–629 (2007)
3. Milner, J. & Medcalf, E. A. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65, 765–774 (1991)
4. Harvey, M. et al. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat. Genet. 9, 305–311 (1995)
5. de Vries, A. et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc. Natl. Acad. Sci. USA 99, 2948–2953 (2002)
6. Olive, K. P. et al. Mutant p53 gain of function in two mouse models of Li–Fraumeni syndrome. Cell 119, 847–860 (2004)
7. Lang, G. A. et al. Gain of function of a p53 hot spot mutation in a mouse model of Li–Fraumeni syndrome. Cell 119, 861–872 (2004)
8. Freed-Pastor, W. A. & Prives, C. Mutant p53: one name, many proteins. Genes Dev. 26, 1268–1286 (2012)
9. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013)
10. Alexandrov, L. B. et al. Clock-like mutational processes in human somatic cells. Nat. Genet. 47, 1402–1407 (2015)
11. Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564–576.e16 (2017)
12. Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779–1784 (2017)
13. Melnikov, A., Rogov, P., Wang, L., Gnirke, A. & Mikkelsen, T. S. Comprehensive mutational scanning of a kinase in vivo reveals substrate-dependent fitness landscapes. Nucleic Acids Res. 42, e112 (2014)
14. Brenan, L. et al. Phenotypic characterization of a comprehensive set of MAPK1/ERK2 missense mutants. Cell Rep. 17, 1171–1183 (2016)
15. Majithia, A. R. et al. Prospective functional classification of all possible missense variants in PPARG. Nat. Genet. 48, 1570–1575 (2016)
16. Drost, J. et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature 521, 43–47 (2015)
17. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848 (2004)
18. Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H. & Weissman, A. M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275, 8945–8951 (2000)
19. Momand, J., Zambetti, G. P., Olson, D. C., George, D. & Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237–1245 (1992)
20. Zhang, Y., Xiong, Y. & Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92, 725–734 (1998)
21. Lin, A. W. & Lowe, S. W. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc. Natl. Acad. Sci. USA 98, 5025–5030 (2001)
22. Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J. & Cleveland, J. L. Disruption of the ARF–Mdm2–p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 13, 2658–2669 (1999)
23. Khosravi, R. et al. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc. Natl. Acad. Sci. USA 96, 14973–14977 (1999)
24. Friedman, P. N., Chen, X., Bargonetti, J. & Prives, C. The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc. Natl. Acad. Sci. USA 90, 3319–3323 (1993)
25. Wang, P. et al. p53 domains: structure, oligomerization, and transformation. Mol. Cell. Biol. 14, 5182–5191 (1994)
26. Clarke, A. R. et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849–852 (1993)
27. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A. & Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847–849 (1993)
28. Lowe, S. W., Ruley, H. E., Jacks, T. & Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957–967 (1993)
29. Lukin, D. J., Carvajal, L. A., Liu, W. J., Resnick-Silverman, L. & Manfredi, J. J. p53 promotes cell survival due to the reversibility of its cell-cycle checkpoints. Mol. Cancer Res. 13, 16–28 (2015)
30. Bunz, F. et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497–1501 (1998)
31. Bunz, F. et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104, 263–269 (1999)
32. Bouaoun, L. et al. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum. Mutat. 37, 865–876 (2016)
33. Kato, S. et al. Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl. Acad. Sci. USA 100, 8424–8429 (2003)
34. Mathe, E. et al. Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res. 34, 1317–1325 (2006)
35. André, F. et al. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov. 7, 818–831 (2017)
36. Rideout, W. M. 3rd, Coetzee, G. A., Olumi, A. F. & Jones, P. A. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 249, 1288–1290 (1990)
37. Tornaletti, S., Rozek, D. & Pfeifer, G. P. The distribution of UV photoproducts along the human p53 gene and its relation to mutations in skin cancer. Oncogene 8, 2051–2057 (1993)
38. Aguilar, F., Hussain, S. P. & Cerutti, P. Aflatoxin B1 induces the transversion of G-- > T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl. Acad. Sci. USA 90, 8586–8590 (1993)
39. Puisieux, A., Lim, S., Groopman, J. & Ozturk, M. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res. 51, 6185–6189 (1991)
40. Bressac, B., Kew, M., Wands, J. & Ozturk, M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350, 429–431 (1991)
41. Hsu, I. C. et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350, 427–428 (1991)
42. Brash, D. E. et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 88, 10124–10128 (1991)
43. Pierceall, W. E., Mukhopadhyay, T., Goldberg, L. H. & Ananthaswamy, H. N. Mutations in the p53 tumor suppressor gene in human cutaneous squamous cell carcinomas. Mol. Carcinog. 4, 445–449 (1991)
44. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012)
45. Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570–575 (2012)
46. Seashore-Ludlow, B. et al. Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov. 5, 1210–1223 (2015)
47. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013)
48. Jeay, S. et al. A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. eL ife 4, e06498 (2015)
49. Cowley, G. S. et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci. Data 1, 140035 (2014)
50. Brinkman, E. K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168 (2014)
51. Dyer, B. W., Ferrer, F. A., Klinedinst, D. K. & Rodriguez, R. A noncommercial dual luciferase enzyme assay system for reporter gene analysis. Anal. Biochem. 282, 158–161 (2000)
52. Bennett, R. P., Cox, C. A. & Hoeffler, J. P. Fusion of green fluorescent protein with the Zeocin-resistance marker allows visual screening and drug selection of transfected eukaryotic cells. Biotechniques 24, 478–482 (1998)